Alternatives to Prednisolone for Vasculitis
For ANCA-associated vasculitis (AAV), avacopan (30 mg twice daily) is the most evidence-based alternative to prednisolone, achieving non-inferior remission rates while potentially improving kidney outcomes and reducing glucocorticoid-related toxicity. 1
Primary Glucocorticoid Alternatives
Avacopan (C5a Receptor Antagonist)
Avacopan represents the only proven glucocorticoid replacement in AAV. The ADVOCATE trial demonstrated that avacopan achieved 72.3% remission at 26 weeks versus 70.1% with prednisolone, meeting non-inferiority criteria 1. Post-hoc analysis showed superior outcomes in patients with eGFR <20 ml/min per 1.73 m², with earlier reduction in albuminuria and improved kidney function recovery 1.
- Dosing: 30 mg orally twice daily, used in combination with rituximab or cyclophosphamide 1
- Key limitation: Patients with eGFR <15 ml/min per 1.73 m² and those requiring mechanical ventilation for alveolar hemorrhage were excluded from trials 1
- Clinical context: Best suited for patients at high risk of glucocorticoid toxicity or with moderate-to-severe kidney disease 1
Reduced-Dose Glucocorticoid Strategies
While not eliminating prednisolone entirely, the LoVAS trial demonstrated that reduced-dose prednisolone (0.5 mg/kg/day) combined with rituximab was non-inferior to high-dose (1 mg/kg/day) for remission induction, with less severe infections 1. This approach excluded patients with eGFR <15 ml/min per 1.73 m² and severe alveolar hemorrhage, and was conducted in a Japanese population with predominantly MPO-ANCA vasculitis 1.
Immunosuppressive Agents (Require Some Glucocorticoid)
These agents reduce but do not eliminate glucocorticoid requirements:
For Remission Induction
Rituximab (preferred for relapsing disease):
- 375 mg/m² IV weekly × 4 weeks 1
- Superior to cyclophosphamide in PR3-ANCA subgroup (OR 2.11) and relapsing disease (OR 3.57 at 6 months) 1
- Allows lower total glucocorticoid exposure compared to cyclophosphamide regimens 1
Cyclophosphamide (oral or IV):
- Oral: 2 mg/kg/day for 3 months (reduce for age: 1.5 mg/kg/day if >60 years, 1.0 mg/kg/day if >70 years) 1
- IV: 15 mg/kg at weeks 0,2,4,7,10,13 (reduce for age: 12.5 mg/kg if >60 years, 10 mg/kg if >70 years) 1
Methotrexate (for non-organ-threatening disease):
- 20-25 mg/week (oral or parenteral) 2
- Critical caveat: Higher relapse rate and more late damage versus cyclophosphamide 1
- Contraindicated if GFR <60 ml/min per 1.73 m² 1
Mycophenolate mofetil (for non-life-threatening disease):
- 2000 mg/day in divided doses (may increase to 3000 mg/day) 1
- Important distinction: Similar remission rates to cyclophosphamide in MPO-ANCA, but much higher relapse risk in PR3-ANCA (MYCYC trial) 1
- Best reserved for MPO-ANCA subgroup without rapidly progressive kidney disease 1
For Maintenance Therapy
After achieving remission, these agents allow glucocorticoid tapering to low doses (5-7.5 mg/day):
- Rituximab: 500 mg IV every 6 months or 1000 mg every 4 months 1
- Azathioprine: 1.5-2 mg/kg/day 1
- Methotrexate: Up to 25 mg/week (avoid if GFR <60 ml/min per 1.73 m²) 1
- Mycophenolate mofetil: 2000 mg/day 1
Clinical Decision Algorithm
For severe/organ-threatening AAV:
- If high glucocorticoid toxicity risk → Consider avacopan + rituximab/cyclophosphamide 1
- If relapsing disease → Rituximab preferred over cyclophosphamide 1
- If PR3-ANCA → Rituximab superior to cyclophosphamide 1
- If MPO-ANCA without rapid progression → MMF acceptable alternative 1
For non-organ-threatening AAV:
- Rituximab + reduced-dose glucocorticoids (0.5 mg/kg/day) 1
- Methotrexate or MMF as alternatives (if normal kidney function) 2
For EGPA: The evidence base is weaker; mepolizumab (300 mg SC every 4 weeks) is recommended for relapsing/refractory disease without organ-threatening manifestations 3
Critical Caveats
- No agent completely eliminates glucocorticoid need except avacopan in selected AAV patients 1
- Plasma exchange does not replace glucocorticoids—it's an adjunctive therapy for severe kidney disease (SCr >300 μmol/L) or diffuse alveolar hemorrhage 1
- Refractory disease: Switch between rituximab and cyclophosphamide; refer to expert centers 2
- All alternatives require careful patient selection based on ANCA subtype, disease severity, kidney function, and relapse history
The 2024 KDIGO guidelines 1 represent the most current evidence and should guide contemporary practice, superseding older recommendations from 2009 2.